Cryopreservation and supply chain fragility in clinical-grade cell products

Reading time: 7 minutes

A vial of clinical-grade stem cells or derivative cell products can survive years in liquid nitrogen at minus 196 degrees Celsius. It can also be destroyed in minutes by a mishandled thaw. Between those two states lies a chain of custody, equipment, protocols, and human decisions. For therapeutic applications these may determine whether the product a patient receives is the same as the product that was banked.

Cryopreservation is the technology that makes dissemination of life sciences applications such as cell therapy possible: the bridge between centralised manufacturing and clinical use at sites that may be hundreds or thousands of miles away. When it works well, it is invisible. When it fails, the consequences are rejected batches, delayed treatments, and in rare cases, patient harm. This article, part of the Pillar 2 series on why ancillary technologies fail, examines why the cold chain remains one of the most fragile links in the stem cell product pathway.

What freezing does to cells

The damage that cryopreservation inflicts is physical and biochemical. As temperature falls, ice forms first in the extracellular medium. The crystalline structure of ice excludes dissolved solutes, concentrating them in the remaining liquid and increasing its osmolarity. Cells respond by losing water, shrinking under osmotic stress. If cooling is too slow, prolonged exposure to concentrated solutes damages membranes and proteins. If cooling is too fast, water inside the cell freezes before it can escape, that can form intracellular ice crystals that rupture internal structures [1].

The standard protective strategy uses dimethyl sulfoxide (DMSO) as a cryoprotective agent, typically at 10 per cent concentration, combined with controlled-rate cooling at roughly one degree Celsius per minute. DMSO penetrates cell membranes and reduces ice crystal formation. It is effective, inexpensive, and has decades of clinical track record. It is also cytotoxic above freezing temperatures, meaning it must be removed from the product before administration to patients [3]. This post-thaw wash step adds time, complexity, and a further source of variability to the clinical workflow.

The thaw itself is equally critical. A cryobag removed from liquid nitrogen warms rapidly in ambient air, and if the warming rate is uncontrolled, the sample passes through a temperature range where ice can recrystallise and cause additional damage. Standard practice is rapid thawing in a water bath at 37 degrees Celsius, with the endpoint judged by the operator as the moment the last visible ice disappears. This subjective judgement varies between operators, and in the hands of an inexperienced person, the result is unacceptably variable cell recovery [1].

Slow freezing and vitrification

The controlled-rate slow freezing described above is the dominant method in stem cell manufacturing because it scales to the volumes that cell banking and clinical production require: millions to billions of cells frozen in bags or vials in a single run. It is the method on which this article centres.

There is, however, a fundamentally different approach. Vitrification uses very high concentrations of cryoprotective agents combined with extremely rapid cooling to solidify the sample into a glass-like amorphous state, bypassing ice crystal formation entirely. Because no ice forms, the mechanical damage that defines slow freezing is largely avoided [2].

Vitrification has become the method of choice in reproductive medicine for preserving eggs (oocytes), early embryos, and small numbers of stem cell colonies. Its strength is that it achieves very high survival rates for individual cells and small cell groups, which makes it indispensable for assisted reproduction in both human fertility treatment and animal breeding, and for conservation efforts involving species preservation where every gamete and embryo is precious.

The limitation is one of scale. Vitrification requires rapid heat transfer across the sample, which constrains sample volume to microlitres. It also demands precise manual handling, high concentrations of cryoprotectants that can be toxic if exposure time is not tightly controlled, and rapid transitions between solutions. These characteristics make it technically demanding and poorly suited to the large-volume, standardisable workflows needed for clinical cell therapy manufacturing. For the ancillary TechBio company, the distinction matters: the cryopreservation challenges your customers face will differ depending on whether they are banking bulk cell populations for therapy (slow freezing) or preserving individual eggs and embryos for reproductive applications (vitrification). Both represent product opportunities, but the engineering and validation requirements are different.

Post-thaw viability is not post-thaw function

Viability counts taken immediately after thawing typically look encouraging. Trypan blue exclusion routinely reports post-thaw viability above 80 per cent. But viability measured at the point of thaw is a poor predictor of how cells will perform over the hours and days that follow. Research on human embryonic stem cells has shown that apparent viability can be high immediately after thaw but decline steadily over subsequent hours as apoptotic pathways, activated by the stresses of freezing and thawing, take effect [4]. Cells that appear alive by membrane integrity assays may already be committed to programmed death.

For clinical products, what matters is not survival at time zero but function at time of use. A cryopreserved stem cell therapy must retain its critical quality attributes after thaw: viability, phenotype, and potency. Demonstrating this requires validated assays that go beyond membrane integrity. It also requires that the time between thaw and clinical administration is tightly controlled, since cell properties can change during the hold period [1].

The Pillar 1 article on key methods introduced cryopreservation as a core technique. The characterisation gaps article in this Pillar 2 series examined why current assays may not capture post-thaw functional quality. Cryopreservation sits at the intersection of both problems: it introduces variability, and the tools to detect that variability are incomplete.

The supply chain problem

For a cell therapy to move from a manufacturing facility to a clinical trial site, the product must remain within a defined temperature range continuously. This cold chain involves controlled-rate freezers, liquid nitrogen storage vessels, shipping containers with validated thermal performance, and trained personnel at every handoff point. Any interruption, a delayed shipment, a faulty sensor, a dewar that runs out of liquid nitrogen, can compromise the product irreversibly.

The challenge intensifies with distributed clinical trials. A product manufactured at one site and shipped to dozens of hospital pharmacies across multiple countries encounters different logistics infrastructure, different handling procedures, and different levels of staff training at each point. Batch-to-batch variability that was manageable in a single-site manufacturing environment becomes a systemic problem when the product must survive a multi-step cold chain.

From our own experience at Roslin Cells banking and distributing clinical-grade pluripotent stem cell lines, and subsequently through the European Bank for Induced Stem Cells (EBiSC) distributing quality-controlled iPSC lines across laboratories in multiple countries [5, 6], the practical difficulties of maintaining product integrity through shipping and storage are routinely underestimated. A cell line that performs well in the originating laboratory may behave differently after intercontinental shipment, not because of any change to the cells themselves but because of what happened to them in transit.

What this means for TechBio

For the ancillary technology company, cryopreservation presents both risks and opportunities.

If your product is a culture medium, scaffold, or reagent, its performance should be validated not only on freshly passaged cells but on cells that have been cryopreserved and thawed under realistic conditions. Cells emerging from a freeze-thaw cycle are stressed, and their response to your product may differ from that of cells in continuous culture. Validation data generated exclusively on fresh cells may not predict field performance.

If your product is a cryopreservation medium, container, or controlled-rate freezer, the bar for clinical acceptance is high. The product must demonstrate consistent post-thaw recovery across cell types, operators, and conditions, with documented performance under the shipping and handling stresses of a real supply chain. The path from research-grade convenience to clinical-grade reliability is the same transition described in the regulatory cliff article in this series.

If your product is a monitoring or tracking system for cold chain management, the market need is real and growing. Regulatory agencies expect traceability throughout the product lifecycle, and the cell therapy industry does not yet have a standardised infrastructure for real-time temperature monitoring, deviation alerting, and chain-of-custody documentation across multi-site supply chains.

Alternatives to DMSO-based cryopreservation are under active investigation. Researchers are exploring combinations of sugars, alcohols, and proteins as cryoprotective agents, with some formulations matching or exceeding DMSO performance in laboratory settings [3]. Machine learning has been applied to optimise multi-component cryopreservation media for iPSCs [3]. These are early-stage developments, and no DMSO-free medium has yet been validated in a clinical cell therapy product. For the TechBio company, this represents a significant development opportunity, but one that requires the clinical validation infrastructure described in the GMP article.

The systemic view

Cryopreservation is not an isolated step. It interacts with everything upstream and downstream. The reproducibility of a manufacturing process depends in part on the consistency of thawed starting materials. The success of scale-up depends on whether banked cell stocks retain their properties through repeated freeze-thaw cycles during process development. The adequacy of characterisation depends on assays that can detect post-thaw damage that viability counts miss.

For the ancillary TechBio company, the lesson is that cryopreservation is not someone else's problem. If your product touches cells at any point in a workflow that includes a freeze-thaw step, the cold chain is part of your validation scope.

References

[1] Meneghel J, Kilbride P and Morris GJ (2020) Cryopreservation as a Key Element in the Successful Delivery of Cell-Based Therapies—A Review. Front. Med. 7:592242. doi: 10.3389/fmed.2020.592242

[2} SchieweMCMullenSF. Vitrification: Fundamental principles and its application for cryopreservation of human reproductive cells, In: BozkurtY editor.Cryopreservation Biotechnology in Biomedical and Biological Sciences,, London: IntechOpen (2018). p. 91–105. 10.5772/intechopen.79672

[3] Dobruskin L, et al. Cryopreservation practices in clinical and preclinical iPSC-based cell therapies: current challenges and future directions. Biotechnol Prog. 2025;41(2):e70031. DOI: 10.1002/btpr.70031

[4] Hunt CJ. Cryopreservation of human stem cells for clinical application: a review. Transfus Med Hemother. 2011;38(2):107-123. DOI: 10.1159/000326623

[5] De Sousa PA, Downie JM, Tye BJ, Bruce K, Dand P, Dhanjal S, Serhal P, Harper J, Turner M, Bateman M. Development and production of good manufacturing practice grade human embryonic stem cell lines as source material for clinical application. Stem Cell Res. 2016 Sep;17(2):379-390. doi: 10.1016/j.scr.2016.08.011. Epub 2016 Aug 26. PMID: 27639108.

[6] De Sousa PA, Steeg R, Kreisel B, Allsopp TE. Hot Start to European Pluripotent Stem Cell Banking. Trends Biotechnol. 2017;35(7):573-576. DOI: 10.1016/j.tibtech.2017.03.004

About StemCells.Help

StemCells.Help is an advisory consultancy that aids innovation and real-world impact of life science applications built on developmental and stem cell biology. Founded by Dr Paul De Sousa, it draws on over four decades of experience spanning early embryo development, animal cloning, pluripotent stem cell manufacturing, and technology commercialisation. If you build tools for these domains or work in an emerging application where the biology is the enabling technology, StemCells.Help can provide experienced scientific counsel to ground your decisions. To discuss your needs, talk to Paul.

ORCID: 0000-0003-0745-2504

Web: stemcells.help